文献速递免疫规划

基于猿腺病毒36载体的多阶段疟疾疫苗prime-boost免疫方案在小鼠中诱导保护性免疫

A prime-boost immunization regimen based on a simian adenovirus 36 vectored multi-stage malaria vaccine induces protective immunity in mice.
PubMed 文献 · Vaccine · 2017-05-05

研究开发了基于约氏疟原虫红前期CSP和红内期MSP1抗原的实验性疫苗PyCMP,并测试以猿腺病毒36(SAd36)为载体的异源prime-boost方案。SAd36PyCMP较Ad5PyCMP增强特异性CD8+ T细胞应答、诱导相似抗体滴度,并在约氏疟原虫感染攻击后降低寄生虫负荷。

要点

  • SAd36PyCMP可增强特异性CD8+ T细胞应答,抗体滴度与Ad5PyCMP方案相似。
  • SAd36PyCMP免疫小鼠在约氏疟原虫攻击后寄生虫负荷低于Ad5PyCMP免疫小鼠。
  • SAd36不感染人类且不被抗Ad5抗体中和,可作为候选病毒载体。

核心结论

  • 重组SAd36PyCMP可增强特异性CD8+ T细胞应答,并在约氏疟原虫感染攻击后较Ad5PyCMP免疫小鼠降低寄生虫负荷。

研究设计与样本

  • 研究构建基于约氏疟原虫红前期CSP和红内期MSP1抗原的实验性疫苗PyCMP,并在小鼠中测试含Ad5或SAd36载体的异源prime-boost免疫方案。

主要发现

  • SAd36PyCMP较含Ad5PyCMP的免疫方案增强特异性CD8+ T细胞应答,并诱导相似抗体滴度。
  • SAd36PyCMP免疫小鼠在约氏疟原虫感染攻击后寄生虫负荷低于Ad5PyCMP免疫小鼠。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Malaria remains a considerable burden on public health. In 2015, the WHO estimates there were 212 million malaria cases causing nearly 429,000 deaths globally. A highly effective malaria vaccine is needed to reduce the burden of this disease. We have developed an experimental vaccine candidate (PyCMP) based on pre-erythrocytic (CSP) and erythrocytic (MSP1) stage antigens derived from the rodent malaria parasite P. yoelii. Our protein-based vaccine construct induces protective antibodies and CD4+ T cell responses. Based on evidence that viral vectors increase CD8+ T cell-mediated immunity, we also have tested heterologous prime-boost immunization regimens that included human adenovirus serotype 5 vector (Ad5), obtaining protective CD8+ T cell responses. While Ad5 is commonly used for vaccine studies, the high prevalence of pre-existing immunity to Ad5 severely compromises its utility. Here, we report the use of the novel simian adenovirus 36 (SAd36) as a candidate for a vectored malaria vaccine since this virus is not known to infect humans, and it is not neutralized by anti-Ad5 antibodies. Our study shows that the recombinant SAd36PyCMP can enhance specific CD8+ T cell response and elicit similar antibody titers when compared to an immunization regimen including the recombinant Ad5PyCMP. The robust immune responses induced by SAd36PyCMP are translated into a lower parasite load following P. yoelii infectious challenge when compared to mice immunized with Ad5PyCMP.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Fonseca JA, McCaffery JN, Kashentseva E, et al. A prime-boost immunization regimen based on a simian adenovirus 36 vectored multi-stage malaria vaccine induces protective immunity in mice. Vaccine. 2017. PMID: 28483199. doi:10.1016/j.vaccine.2017.04.062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。